3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: What's it all about?

Clinical Pharmacology and Therapeutics

Volumn 75, Issue 5, 2004, Pages 381-385

  Kim, Richard B ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BILE ACID; BROMSULFOPHTHALEIN; CERIVASTATIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIGOXIN; ENALAPRIL; ESTRADIOL 17 GLUCURONIDE; ESTRONE SULFATE; FEXOFENADINE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER PROTEIN; OCHRATOXIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 4; ORGANIC ANION TRANSPORTING POLYPEPTIDE 8; ORGANIC ANION TRANSPORTING POLYPEPTIDE B; ORGANIC ANION TRANSPORTING POLYPEPTIDE C; OUABAIN; PRASTERONE SULFATE; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; TAUROCHOLIC ACID; TEMOCAPRILAT; THYROXINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

DRUG DISPOSITION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; GENETIC VARIABILITY; HUMAN; LIVER; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPORT KINETICS;

ANIMALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORT POLYPEPTIDE C; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS;

EID: 2042539351     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2004.01.004     Document Type: Note

References (17)

1. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 8:1997;161-170
2. Marzolini C., Paus E., Buclin T., Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance. Clin Pharmacol Ther. 75:2004;13-33
3. Kim R.B. Transporters and drug disposition. Curr Opin Drug Discov Devel. 3:2000;94-101
4. Tirona R.G., Kim R.B. Pharmacogenomics of organic anion-transporting polypeptides (OATP). Adv Drug Deliv Rev. 54:2002;1343-1352
5. Tirona RG, Kim RB. Pharmacogenomics of drug transporters. In: Licinio J, Wong ML, editors. Pharmaco-genomics: the search of individualized therapeutics. Weinheim: Wiley-VCH; 2002 p. 179-214.
6. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21
7. Hagenbuch B., Meier P.J. Organic anion transporting polypeptides of the OATP/SLC21 family phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447:2004;653-665
8. Abe T., Kakyo M., Tokui T., Nakagomi R., Nishio T., Nakai D., et al. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem. 274:1999;17159-17163
9. Hsiang B., Zhu Y., Wang Z., Wu Y., Sasseville V., Yang W.P., et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 274:1999;37161-37168
10. Konig J., Cui Y., Nies A.T., Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol. 278:2000;G156-164
11. Kullak-Ublick G.A., Ismair M.G., Stieger B., Landmann L., Huber R., Pizzagalli F., et al. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 120:2001;525-533
12. Abe T., Unno M., Onogawa T., Tokui T., Kondo T.N., Nakagomi R., et al. Lst-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 120:2001;1689-1699
13. Nakai D., Nakagomi R., Furuta Y., Tokui T., Abe T., Ikeda T., et al. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther. 297:2001;861-867
14. Shitara Y., Itoh T., Sato H., Li A.P., Sugiyama Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther. 304:2003;610-616
15. Bolego C., Poli A., Cignarella A., Catapano A.L., Paoletti R. Novel statins pharmacological and clinical results. Cardiovasc Drugs Ther. 16:2002;251-257
16. Tirona R.G., Leake B.F., Merino G., Kim R.B. Polymorphisms in OATP-C identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem. 276:2001;35669-35675
17. Nishizato Y., Ieiri I., Suzuki H., Kimura M., Kawabata K., Hirota T., et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 73:2003;554-565